Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05461430 · ClinicalTrials.gov registry record
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
A clinical trial of Carcinoma, Non-Small Cell Lung and Carcinoma, Renal Cell, sponsored by Travera.
- Recruiting
- Registry status
- 200
- Enrollment target
- 1
- Study location
NCT05461430 is a study of Carcinoma, Non-Small Cell Lung and Carcinoma, Renal Cell that is actively recruiting participants, run by Travera. The registered enrollment target is 200 participants, below the 322-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (38% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05461430, a study of Carcinoma, Non-Small Cell Lung and Carcinoma, Renal Cell, is actively recruiting participants, sponsored by Travera.
- RECRUITING
- Registry status
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of this study, sponsored by Travera Inc. in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using isolated tumor cells from various specimen formats including malignant fluids such as pleural effusions and ascites, core needle biopsies, fine needle aspirates, or resections.
Conditions Studied
Study Locations (1)
California
- xCures - Oakland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2022-07-15 |
| Est. Completion | 2028-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05461430
The ClinicalTrials.gov registry entry for NCT05461430 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 322-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (38% lower). The listed sponsor is Travera, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 0 interventions.
NCT05461430 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05461430 about?
NCT05461430 is a clinical study titled "Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)". The primary objective of this study, sponsored by Travera Inc. in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using isolated tumor cells from various specimen formats including malig...
What is the current status of trial NCT05461430?
This trial is currently recruiting. The enrollment target is 200 participants. The study started on 2022-07-15. Estimated completion is 2028-07.
What conditions does trial NCT05461430 study?
This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung, Carcinoma, Renal Cell, Carcinoma, Carcinoma, Hepatocellular, Carcinoma, Pancreatic Ductal.
Who is sponsoring clinical trial NCT05461430?
This trial is sponsored by Travera, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05461430 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Non-Small Cell Lung
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
RECRUITING · Phase 1
-
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 3
-
Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer
RECRUITING · Phase 2
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.